



**SDI Review Form 1.6**

Journal Name:	<a href="#">International Journal of Medical and Pharmaceutical Case Reports</a>
Manuscript Number:	<b>Ms_IJMPCR_26538</b>
Title of the Manuscript:	<b>Novel Therapy May Be the First Line Treatment for Multiple Myeloma but Should Not Be the Last Word: Two Cases Illustrated</b>
Type of the Article	<b>Case study</b>

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



**SDI Review Form 1.6**

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	In the current case study, a significant contribution for the bio-medical and therapeutic practice is made, in particular in the field of the malignant diseases and disorders. I have some notes, connected mainly with the grammatical features, which could make the paper clearer for everybody, who would read it. So, the start of the sentence on lane 26 - "In the most patients...", as well as on lane 60 - "healthy baby in the middle of 2007". Also, the other my suggestion is in the characteristics of both patients, "she" and "he" be changed/alternated from time to time with "the patient"; "this female patient"/"this male patient", respectively; the woman/the man, respectively; this woman/this man, respectively; after which the next sentence might already begin again with "she"/"he", respectively, etc.	
<b>Minor</b> REVISION comments	The authors of the current paper develop novel combined therapeutic programs of two significant patients with forms of diagnosed MM, by combination of radiotherapy and cocktail of several chemotherapeutic preparations, with new therapeutic and reparation strategies as transplantation of autologous stem cells, which allows maximally safe therapeutic procedures with minimal existence of unwished side effects. In the cases with polygene and multi-factor diseases and disorders, where the malignancies beyond, the determination and development of individual therapeutic strategy for each case is very important because of the different primary causes, leading to the general common picture	
<b>Optional/General</b> comments		

Reviewer Details:

Name:	<b><i>Iskra Ventseslavova Sainova</i></b>
Department, University & Country	<b><i>Bulgarian Academy of Sciences (IEMPAM - BAS) in Sofia, Bulgaria</i></b>